BIOLICAN- INSERM- AAP Research Company(s) 2019 (Q3683260): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): BIOLICAN aims to develop an innovative non-invasive technological device capable of detecting specific molecular signatures in the blood of lung cancer patients in order to improve early diagnosis and management of the disease., translated_summary) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
BIOLICAN- INSERM- AAP Research Company(s) 2019 | |||
Revision as of 18:19, 18 November 2021
Project Q3683260 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BIOLICAN- INSERM- AAP Research Company(s) 2019 |
Project Q3683260 in France |
Statements
295,632.0 Euro
0 references
397,402.0 Euro
0 references
74.39 percent
0 references
1 January 2020
0 references
31 December 2022
0 references
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
0 references
BIOLICAN vise à développer un dispositif technologique innovant non invasif capable de détecter des signatures moléculaires spécifiques dans le sang des patients atteints de cancer du poumon afin d’améliorer le diagnostic précoce et la prise en charge de la maladie. (French)
0 references
BIOLICAN aims to develop an innovative non-invasive technological device capable of detecting specific molecular signatures in the blood of lung cancer patients in order to improve early diagnosis and management of the disease. (English)
18 November 2021
0 references
Identifiers
MP0021775
0 references